Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
about
Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and backPharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in JapanHypersensitivity reactions to HIV therapy.Epidemiology and risk factors for drug allergy.Low prevalence of human leukocyte antigen-B*5701 in HIV-1-infected Chinese subjects: a prospective epidemiological investigation.The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in ThailandPrevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use.HLA and pharmacogenetics of drug hypersensitivity.Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome.Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients.Development of an HIV clinical cohort database for enhancing epidemiologic surveillance in Hong Kong.HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
P2860
Q26784638-F6FF8FEC-6B1E-4FA0-8C5F-C1E871EEF20DQ34342305-C1775F59-9E9F-4952-ABE3-A7ACE51F6915Q34503521-EA833322-B88A-4FAA-A85C-532B5CDF0E75Q34976463-AF9C0BAD-156C-4EFB-9CA7-4A6E79F92C46Q34976470-DDA541DC-6A03-4E2A-8A82-8A20722AFCC4Q35977574-FA6157A6-4F12-4833-AB3F-5DE7105004AAQ36267146-4BFBDAD6-DF28-4DC0-9AC1-58433128CC1DQ37638863-E45B700E-4CF2-40DE-A745-E6102D8288AEQ38037649-3B659DF8-23EC-4E7D-8D1A-61202A237838Q38080040-F22738DE-706F-4659-BA06-6BDCD82BD2ADQ38122461-7D492C00-6D24-4526-8381-6BF99DD0FFBCQ38871356-FAEB9606-2DBE-4A5D-91D3-D14C6FEDAC73Q38941642-F847BF6A-E636-48A1-B994-6E4AC1FA4F0BQ42259925-F6BD39D1-D60E-4754-AE50-1DA0C2902FC3Q46056916-7E8CE18F-EDBC-4C34-85FC-95190F1DA404Q53434514-CC802582-C99E-4645-98DD-312499BF7A93
P2860
Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
@en
Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
@nl
type
label
Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
@en
Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
@nl
prefLabel
Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
@en
Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
@nl
P2093
P50
P356
P1476
Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
@en
P2093
Jae Hyun Jeon
Kang Won Choe
Myoung Hee Park
Pyoeng Gyun Choe
Sang-Won Park
P304
P356
10.1086/595890
P407
P577
2009-02-01T00:00:00Z